PANCREATIC-CANCER AND ANDROGEN METABOLISM - HIGH ANDROSTENEDIONE AND LOW TESTOSTERONE SERUM LEVELS

被引：21

作者：

FERNANDEZDELCASTILLO, C ^{[1
]}

ROBLESDIAZ, G ^{[1
]}

DIAZSANCHEZ, V ^{[1
]}

ALTAMIRANO, A ^{[1
]}

机构：

[1] INST NACL NUTR SALVADOR ZUBIRAN,DEPT GASTROENTEROL,VASCO QUIROGA 15,MEXICO CITY 14000,DF,MEXICO

来源：

PANCREAS | 1990年 / 5卷 / 05期

关键词：

Androgens; Androstenedione; Pancreatic cancer; Testosterone;

D O I：

10.1097/00006676-199009000-00003

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Serum androstenedione and testosterone levels were measured in 39 male patients with pancreatic cancer, and compared with the values obtained from 37 male patients with chronic pancreatitis or benign obstructive jaundice, and with those from 36 male patients with other gastrointestinal malignancies. Mean androstenedione values were significantly higher in the pancreatic cancer patients when compared to both control groups, and mean testosterone levels were significantly lower. The testosterone/androstenedione ratio was calculated and was also found to be significantly lower in the patients with pancreatic cancer. There was no difference in this ratio or in the androstenedione or testosterone levels when comparing both control groups. In two patients with stage I pancreatic cancer, serum androstenedione and testosterone levels were significantly altered, and returned to normal values after successful resection. These results confirm previous findings indicating that there is significant derangement in the androgen profile of patients with pancreatic cancer. © 1990 Raven Press, Ltd., New York.

引用

页码：515 / 518

页数：4

共 16 条

[1]

Connolly M.M., Dawson P.J., Michelassi F., Moosa A.R., Lowenstein F., Survival in 1001 patients with carcinoma of the pancreas, Ann Surg, 206, pp. 366-370, (1987)

[2]

Warshaw A.L., Swanson R.S., Pancreatic cancer in 1988. Possibilities and probabilities, Ann Surg, 208, pp. 541-553, (1988)

[3]

Levin D.L., Connelly R.R., Deveja S.S., Demographic characteristics of cancer of the pancreas: Mortality, incidence and survival, Cancer, 47, pp. 1456-1468, (1981)

[4]

Czemichow P., Lerebours E., Hecktsweiler P., Colin R., Epiddmiologie temporo-spatiale du cancer du páncreas: étude de mortality intemationale et francaise, Gastroenterol Clin Biol, 9, pp. 767-775, (1985)

[5]

Greenway B., Iqbal M.J., Johnson P.J., Williams R., Low serum testosterone concentration in patients with carcinoma of the pancreas, Br Med J, 286, pp. 93-95, (1983)

[6]

Shearer M.G., Taggart D., Gray C., Et al., Useful differentiation between pancreatic carcinoma and chronic pancreatitis by testosterone assay, Digestion, 30, pp. 106-107, (1984)

[7]

Robles-Diaz G., Diaz-Sanchez V., Mendez J.P., Altamirano A., Wolpert E., Low serum testosterone/dihydrotestosterone ratio in patients with pancreatic carcinoma, Pancreas, 2, pp. 38-43, (1987)

[8]

Greenway B., Duke D., Pym B., Iqbal M.J., Johnson P.J., Williams R., The control of human pancreatic adenocarci-noma xenografts in nude mice by hormone therapy, Br J Surg, 69, pp. 595-597, (1982)

[9]

Lhoste E.F., Roebuck B.D., Stem J.E., Longnecker D.S., Effect of orchiectomy and testosterone on the early stages of azaserine induced pancreatic carcinogenesis in the rat, Pancreas, 2, pp. 38-43, (1987)

[10]

Fernadez Del Castillo C., Diaz-Sanchez V., Varela-Fascinetto G., Odor-Morales A., Altamirano A., Robles-Diaz G., Testosterone biotransformation by the isolated perfused canine pancreas, Pancreas, 4, (1989)

← 1 2 →